Literature DB >> 20069457

14-3-3 mediated regulation of the tumor suppressor protein, RASSF1A.

Haya Abu Ghazaleh1, Renfred S Chow, Sheryl L Choo, Diana Pham, Jamie D Olesen, Russell X Wong, Christina Onyskiw, Shairaz Baksh.   

Abstract

Death receptor-dependent apoptosis is an important mechanism of growth control. It has been demonstrated that Ras association domain family protein 1A (RASSF1A) is a tumor suppressor protein involved in death receptor-dependent apoptosis. However, it is unclear how RASSF1A-mediated cell death is initiated. We have now detailed 14-3-3 dependent regulation of RASSF1A-mediated cell death. We demonstrate that basal association of RASSF1A with 14-3-3 was lost following stimulation with tumor necrosis factor alpha (TNFalpha) or TNFalpha related apoptosis inducing ligand (TRAIL). Subsequent to the loss of 14-3-3 association, RASSF1A associated with modulator of apoptosis (MOAP-1) followed by death receptor association with either TNFalpha receptor 1 (TNF-R1) or TRAIL receptor 1 (TRAIL-R1). 14-3-3 association required basal phosphorylation by the serine/threonine kinase, glycogen synthase kinase 3beta (GSK-3beta), on serine 175, 178, and 179. Mutation of these critical serines resulted in the loss of 14-3-3 association and earlier recruitment of RASSF1A to MOAP-1, TNF-R1, and TRAIL-R1. Furthermore, stable cells containing a triple serine mutant of RASSF1A [serine (S) 175 to alanine (A) [S175A], S178A, and S179A] resulted in increased basal cell death, enhanced Annexin V staining and enhanced cleavage of poly (ADP-ribose) polymerase (PARP) following TNFalpha stimulation when compared to stable cells containing wild type RASSF1A. RASSF1A-mediated cell death is, therefore, tightly controlled by 14-3-3 association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20069457     DOI: 10.1007/s10495-009-0451-6

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  14 in total

1.  RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines.

Authors:  Jane Levesley; Meryl E Lusher; Janet C Lindsey; Steven C Clifford; Richard Grundy; Beth Coyle
Journal:  Neuro Oncol       Date:  2011-08-31       Impact factor: 12.300

2.  Targeted polyubiquitylation of RASSF1C by the Mule and SCFβ-TrCP ligases in response to DNA damage.

Authors:  Xin Zhou; Ting-Ting Li; Xu Feng; Esther Hsiang; Yue Xiong; Kun-Liang Guan; Qun-Ying Lei
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

Review 3.  14-3-3 proteins as signaling integration points for cell cycle control and apoptosis.

Authors:  Alexandra K Gardino; Michael B Yaffe
Journal:  Semin Cell Dev Biol       Date:  2011-09-14       Impact factor: 7.727

Review 4.  Tumor suppressor C-RASSF proteins.

Authors:  Hiroaki Iwasa; Shakhawoat Hossain; Yutaka Hata
Journal:  Cell Mol Life Sci       Date:  2018-01-20       Impact factor: 9.261

5.  RASSF1A: Not a prototypical Ras effector.

Authors:  Marilyn Gordon; Shairaz Baksh
Journal:  Small GTPases       Date:  2011-05

6.  Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer.

Authors:  Dimitrios Matthaios; Ioanna Balgkouranidou; Anastasios Karayiannakis; Helen Bolanaki; Nikolaos Xenidis; Kyriakos Amarantidis; Leonidas Chelis; Konstantinos Romanidis; Aikaterini Chatzaki; Evi Lianidou; Grigorios Trypsianis; Stylianos Kakolyris
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

7.  Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1.

Authors:  Yong Hoi Lee; Siew Wai Pang; Esther Revai Lechtich; Khalid Shah; Samson Eugin Simon; Suriyan Ponnusamy; Ramesh Narayanan; Chit Laa Poh; Kuan Onn Tan
Journal:  J Cancer Res Clin Oncol       Date:  2020-05-06       Impact factor: 4.553

8.  Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients.

Authors:  Evangelos I Karamitrousis; Ioanna Balgkouranidou; Nikolaos Xenidis; Kyriakos Amarantidis; Eirini Biziota; Triantafyllia Koukaki; Grigorios Trypsianis; Anastasios Karayiannakis; Helen Bolanaki; George Kolios; Evi Lianidou; Stylianos Kakolyris
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

9.  RASSF1 Polymorphisms in Cancer.

Authors:  Marilyn Gordon; Mohamed El-Kalla; Shairaz Baksh
Journal:  Mol Biol Int       Date:  2012-05-31

10.  The cellular functions of RASSF1A and its inactivation in prostate cancer.

Authors:  Karishma S Amin; Partha P Banerjee
Journal:  J Carcinog       Date:  2012-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.